Catalyst overview
Research summary
This catalyst tracks a Phase 2/3 data readout for DM199 (KLK1 protein) in Heart disease, Ischemic stroke. The expected timing is based on the latest available company guidance and may change.
ReMEDy2 trial. 6/21/23- Lifted clinical hold. 4/17/24- First patient dosed. 11/13/24- To submit amended SAP to FDA. 11/12/25- Enrollment near 50% of 200 patients. Interim analysis in H2 2026. 03/31/26:- ReMEDy2 enrollment near 70% for interim; interim analysis timing reaffirmed for H2 2026. 05/07/26:- Enrollment surpassed 70%; interim analysis still planned for Q4 2026 completion. 05/20/26:- ReMEDy2 reached 75% enrollment needed to trigger DSMB interim analysis; completion still expected before year-end 2026. 08/10/26:- ReMEDy2 enrollment surpassed 85%; interim analysis expected Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.